Orange Book product · Generic (ANDA)
TACROLIMUS
TACROLIMUS
At a glance
Apr 17, 2023
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Apr 17, 2023
3 yr 3 mo ago
Today
Pharmaceutical detail
Active ingredient
TACROLIMUS
Strength
EQ 0.5MG BASE
Dosage form
CAPSULE
Route
ORAL
TE code
Not listed
Application
ANDA 210929
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of TACROLIMUS
- 2018PROGRAFBrand (NDA)
NDA 210115 · ASTELLAS
- 2015ENVARSUS XRBrand (NDA)
NDA 206406 · VELOXIS PHARMS INC
- 2013ASTAGRAF XLBrand (NDA)
NDA 204096 · ASTELLAS
- 2000PROTOPICBrand (NDA)
NDA 050777 · LEO PHARMA AS
- 1998PROGRAFBrand (NDA)
NDA 050708 · ASTELLAS
- 1994PROGRAFBrand (NDA)
NDA 050709 · ASTELLAS
- 2025TACROLIMUSGeneric (ANDA)
ANDA 217108 · NEXUS
- 2024TACROLIMUSGeneric (ANDA)
ANDA 215012 · CHENGDU
- 2023TACROLIMUSGeneric (ANDA)
ANDA 212387 · ENCUBE
- 2023TACROLIMUSGeneric (ANDA)
ANDA 210393 · GLENMARK PHARMS LTD
- 2020TACROLIMUSGeneric (ANDA)
ANDA 203740 · ALKEM LABS LTD
- 2020TACROLIMUSGeneric (ANDA)
ANDA 212297 · BIOCON PHARMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
